title: Antisense therapy: potential tool to reduce activity in MS via protein expression inhibition.
authors.affiliation: From the Department of Neurology (R.T.N., A.H.C.) and Hope Center for Neurological Disorders (A.H.C.), Washington University School of Medicine, St. Louis, MO.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Naismith
authors.affiliation: From the Department of Neurology (R.T.N., A.H.C.) and Hope Center for Neurological Disorders (A.H.C.), Washington University School of Medicine, St. Louis, MO. crossa@neuro.wustl.edu.
authors.forename: Anne H
authors.initials: AH
authors.lastname: Cross
mesh_terms: D005260:Female; D006801:Humans; D039441:Integrin alpha4 / Q000737:chemistry* / Q000235:genetics*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D020319:Oligodeoxyribonucleotides, Antisense / Q000627:therapeutic use*
chemical_list: D020319:Oligodeoxyribonucleotides, Antisense; D039441:Integrin alpha4